Assetmark Inc. Reduces Bristol Myers Squibb Stake

Institutional investor trims position in pharmaceutical giant by nearly 30% in Q4

Apr. 18, 2026 at 7:23am

Got story updates? Submit your updates here. ›

A highly detailed, black-and-white close-up image of the gears, levers, and mechanisms that make up the inner workings of a large, industrial-scale bank vault or safe deposit box, conveying a sense of financial security and institutional power through its heavy, metallic components.An extreme close-up of the complex inner workings of a bank's secure vault highlights the tangible, industrial nature of financial institutions.Princeton Today

Assetmark Inc., an institutional investor, reduced its stake in Bristol Myers Squibb Company (NYSE:BMY) by 29.5% during the fourth quarter, according to a recent SEC filing. The firm now owns 169,662 shares of the biopharmaceutical company's stock, valued at $9.15 million as of the end of 2026.

Why it matters

This filing provides insight into the investment decisions of Assetmark Inc., a notable institutional investor. Changes in major shareholders' positions can signal shifts in market sentiment or confidence around a company's prospects.

The details

According to the 13F filing, Assetmark sold 70,960 shares of Bristol Myers Squibb stock during the fourth quarter. The firm now holds a total of 169,662 shares, down from 240,622 shares held at the end of the previous quarter. Bristol Myers Squibb is a major biopharmaceutical company focused on oncology, hematology, immunology, and specialty drug development and commercialization.

  • Assetmark Inc. filed the 13F report disclosing the reduced stake on April 18, 2026.
  • The filing covers Assetmark's holdings as of the end of the fourth quarter of 2025.

The players

Assetmark Inc.

An institutional investment firm that manages assets for clients.

Bristol Myers Squibb Company

A global biopharmaceutical company focused on developing and delivering innovative medicines for serious diseases.

Got photos? Submit your photos here. ›

The takeaway

This filing highlights the shifting investment landscape around Bristol Myers Squibb, as one major institutional investor has chosen to trim its position in the pharmaceutical company. While the reasons behind Assetmark's decision are not explicitly stated, the move could signal broader market trends or concerns that warrant further monitoring of Bristol Myers Squibb's performance and outlook.